Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan

被引：0
|
作者：
Podder, Vivek
Ranjan, Tulika
Bardhan, Mainak
McCracken, Andrea
Hurmiz, Charlie
Ganiyani, Mohammad Arfat
Ahmad, Shahzaib
Mahtani, Reshma L.
Ahluwalia, Manmeet Singh
机构：
[1] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[2] Guardian Res Network, Spartanburg, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1036
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
    Shitara, Kohei
    Bang, Yung-Jue
    Iwasa, Satoru
    Sugimoto, Naotoshi
    Ryu, Min-Hee
    Sakai, Daisuke
    Chung, Hyun-Cheol
    Kawakami, Hisato
    Yabusaki, Hiroshi
    Lee, Jeeyun
    Saito, Kaku
    Kawaguchi, Yoshinori
    Kamio, Takahiro
    Kojima, Akihito
    Sugihara, Masahiro
    Yamaguchi, Kensei
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25): : 2419 - 2430
  • [32] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab
    Blanchette, P. S.
    Desautels, D. N.
    Pond, G.
    Bartlett, J. M. S.
    Nofech-Mozes, S.
    Yaffe, M.
    Pritchard, K. I.
    CANCER RESEARCH, 2017, 77
  • [33] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
    Blanchette, P. S.
    Desautels, D. N.
    Pond, G. R.
    Bartlett, J. M. S.
    Nofech-Mozes, S.
    Yaffe, M. J.
    Pritchard, K. I.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (01) : 169 - 177
  • [34] Safety of trastuzumab deruxtecan and radiation therapy combination in HER2-positive metastatic breast cancer patients
    Visani, L.
    Ratosa, I.
    Ribnikar, D.
    Becherini, C.
    Bertini, N.
    Bonaparte, I.
    Stefanovski, D.
    Dobnikar, N.
    Desideri, I.
    Mattioli, C.
    Valzano, M.
    Banini, M.
    Salvestrini, V.
    Bernini, M.
    Tommasi, C.
    Nori, J.
    Orzalesi, L.
    Bianchi, S.
    Livi, L.
    Meattini, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 60 - 61
  • [35] Trastuzumab deruxtecan, its efficacy in patients with metastatic HER2-positive breast cancer: a systematic review
    Fernhandho, V.
    Jhoputri, C. Fricilia
    Julian, L.
    Kurniawan, A.
    Huang, I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1337 - S1337
  • [36] Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
    Testa, Stefano
    Dickerson, James C.
    Telli, Melinda
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 11
  • [37] Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 556 - 558
  • [38] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    BREAST CARE, 2021, 16 (03)
  • [39] Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
    Nakajima, Hiromichi
    Harano, Kenichi
    Nakai, Tokiko
    Kusuhara, Shota
    Nakao, Takehiro
    Funasaka, Chikako
    Kondoh, Chihiro
    Matsubara, Nobuaki
    Naito, Yoichi
    Hosono, Ako
    Mitsunaga, Shuichi
    Ishii, Genichiro
    Mukohara, Toru
    BREAST, 2022, 61 : 136 - 144
  • [40] Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
    Chen, Yuanping
    Liu, Chao
    Wen, Xinglin
    Wang, Chen
    He, Jing
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2024, 16 : 1277 - 1283
12345